Clinical Trial Update: Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6). [Phase 3]

View source ↗

Summary

Phase 3 ECZTRA 6 evaluated tralokinumab monotherapy in adolescents with moderate to severe atopic dermatitis; the trial completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Tralokinumab (tralokinumab)

Snippet

Sponsor: LEO Pharma | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2021-10-29